Complications of hysteroscopic Essure â sterilisation: report on 4306 procedures performed in a single centre
|
|
- Avice Lang
- 6 years ago
- Views:
Transcription
1 DOI: /j x Fertility control Complications of hysteroscopic Essure â sterilisation: report on 4306 procedures performed in a single centre B Povedano, a JE Arjona, a E Velasco, a JA Monserrat, a J Lorente, a C Castelo-Branco b a Department of Obstetrics and Gynaecology, Reina Sofía University Hospital, Córdoba, Spain b Institute Clinic of Gynaecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clinic-Institut d Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain Correspondence: Dr C Castelo-Branco, Institut Clínic de Ginecologia, Obstetrícia i Neonatología, Hospital Clínic, Villarroel 170, Barcelona, Spain. castelobranco@ub.edu Accepted 15 January Published Online 23 February Objective To analyse the short-, medium- and long-term complications in women undergoing hysteroscopic tubal sterilisation with the Essure Ò device. Design Retrospective 7-year study. Setting Office hysteroscopic unit in a teaching hospital. Sample A total of 4306 women whoe underwent the Essure Ò sterilisation procedure from 2003 to Methods Data on the success of the procedure and complications arising from outpatient hysteroscopic sterilisation using the Essure Ò system were collected from consecutive women undergoing the procedure over a 7-year period. Main outcome measures Placement rate, successful bilateral tubal occlusion, perioperative adverse events, early postoperative (during the first 3 months of follow-up) and late complications (after the initial 3 months of follow-up). Results A total of 4108 (96.8%) women completed the standard 3-month follow-up protocol. Only 534 (13%) women had undergone the procedure within the previous year. There were 115 (out of 4306; 2.7%) recorded complications, none of which resulted in the need for hospitalisation or discharge later than 2 hours after the procedure. Vasovagal syncope was the most frequently encountered adverse event, occurring in 85 (2.0%) of 4306 cases. In 19 cases, one device was expelled, with most expulsions (14 out of 19) being detected before or during the 3-month follow-up. Conclusions Outpatient hysteroscopic sterilisation using the Essure Ò system is safe, with a low rate of complications. Keywords Adverse events, complications, Essure Ò hysteroscopic tubal sterilisation. Please cite this paper as: Povedano B, Arjona J, Velasco E, Monserrat J, Lorente J, Castelo-Branco C. Complications of hysteroscopic Essure Ò sterilisation: report on 4306 procedures performed in a single centre. BJOG 2012;119: Introduction Hysteroscopic sterilisation using Essure Ò (Conceptus, Mountain View, CA, USA) has been used increasingly throughout the world, especially within the European Union, after the technology was introduced in Compared with classic laparoscopic sterilisation techniques (bipolar coagulation, Hulka clips, Filshie clips and silicone rings), hysteroscopic sterilisation can be performed with less surgical time in an outpatient clinic setting, without the need for surgical incisions or general anaesthesia, and with superior patient tolerance and patient satisfaction. 1 4 However, the ability to complete the procedure is generally lower than traditional laparoscopic approaches. The transcervical route of accessing the fallopian tubes requires proficiency in outpatient hysteroscopy as well as familiarity with the Essure Ò technique. Failure to satisfactorily insert the devices into the fallopian tubes varies from 88 to 98%, 1,4,5 although successful placement appears to be improving as experience amongst gynaecologists increases in conjunction with continued improvements in Essure Ò technology. 6 To date, complications associated with the Essure Ò procedure are thought to be uncommon, and are minor when present. 7 On the other hand, complications with laparoscopy, although rare, can be serious, including organ or ª 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology ª 2012 RCOG 795
2 Povedano et al. vascular injury and problems arising from general anaesthesia. 8,9 Possible adverse events with the Essure Ò procedure are related either to the general hysteroscopic approach or the specific Essure Ò placement technique. Complications such as fluid overload and electrolyte disturbances are unusual, as the distending media for Essure Ò sterilisation is saline solution, and the operating time on average decreases to around 8 minutes, with experience. 10,11 Uterine and cervical trauma is rare, as the procedure is completed with small-diameter continuous-flow hysteroscopes. In a phase- II study, 7% of women reported an adverse event, of which vasovagal syncope was the most prevalent, followed by device expulsion, perforation and unsatisfactory placement. 5 Pain during and after the procedure, bleeding and dyspareunia have also been described. 5 Persistent pain has been reported, but is unusual and, if present, raises the possibility of tubal perforation by the device, which may affect around 1 2% of procedures. 12,13 Migration to the cavity can also occur without tubal perforation. 14 Confirmatory radiological testing with abdominal X-ray, transvaginal ultrasound (TVU) or hysterosalpingogram (HSG), according to local protocols, is mandatory to establish satisfactory device placement and/or tubal occlusion. Early expulsion of a device from the tube and uterine cavity is usually diagnosed at this time, but if this takes place after the 3-month follow-up test it may remain undetected, leaving the patient at risk of an unwanted pregnancy. 15 There is a need for more data regarding the feasibility and safety of hysteroscopic sterilisation. We therefore undertook a study to analyse the practicality and short-, medium- and long-term complications of hysteroscopic tubal sterilisation using the Essure Ò permanent birth control system. Methods All women attending the Andalusia Health Service in Cordoba requesting permanent birth control, and who underwent hysteroscopic sterilisation with the Essure Ò system at the Reina Sofía University Hospital between March 2003 and June 2010 were identified. A total of 4306 women were included in this study carried out from March 2003 to June The inclusion criteria for hysteroscopic sterilisation were women aged years desiring permanent birth control and able to comprehend and sign written consent, attend the 3permanent birth control, and who underwent hysteroscopic sterilisation with the Essmonth follow-up and use contraception until then. Women were excluded if they had abnormal uterine bleeding, active pelvic inflammatory disease or uncertainty about their desire to end their fertility. All procedures were carried out or supervised by four gynaecologists (B.P., E.V., J.M. and J.L.) experienced in the Essure Ò technique. Of the 4306 procedures, 1683 were performed by resident gynaecologists and 293 were performed by external training gynaecologists. The procedures were scheduled to be performed in the follicular phase of the menstrual cycle, unless women were taking oral contraceptives, in which case they were advised to take their pills continuously for at least a month prior to the intervention. All women received premedication with oral ibuprofen and 10 mg of diazepam 1 hour before the procedure. Of the sample, 472 women received paracervical anaesthesia (mepivacaine cloridrate 3%, 7.2 ml) because they found routine gynaecological examination painful, had a tight cervical os or were anxious. 1 A vaginoscopic approach to hysteroscopy was adopted routinely, and the Essure Ò microinserts were placed through the 5F working channel of a 5-mm, continuous-flow, 30 hysteroscope (Karl Storz Endoscopia, Barcelona, Spain), using a saline distension medium. Placement was performed according to the manufacturer s instructions. Placement was considered to be optimal when between one and eight coils remained visible in the uterine cavity. After insertion, the women consulted and completed an oral questionnaire defining their pain experience as none, mild (less than menses), moderate (similar to menses) or severe (more than menses). All women who underwent Essure Ò placement were discharged home on the same day of the procedure. Women were advised to use an alternative contraceptive method until a simple pelvic X-ray examination was performed at least 3 months after the insertion. Placement was considered satisfactory when both devices appeared to be within the tubal lumen, had symmetrical appearance, ends that looked opposite one another and when the distance between the intrauterine ends was not >4 cm. If the position of the devices were not clear in the pelvic X-ray a TVU was performed with recourse to HSG if the ultrasound was equivocal (i.e. if the transversal section of the uterus did not show both devices at the uterotubal junction). In addition, HSG was performed when the placement was not satisfactory (more than eight or less than one coils remaining visible by hysteroscopy, insertion only in one tube or highly difficult procedure). On confirmation of adequate placement at the 3-month follow-up visit, women were advised to rely on the Essure Ò system for contraception. Adverse events were recorded at the time of the procedure, at the 3-month follow-up and at each gynaecological check-up. The telephone number of the unit was given to all the women, who were advised to report any complication. All general practitioners and general gynaecologists in the healthcare reference area were advised to report and refer the subject in the case of complications being detected in Essure Ò users. 796 ª 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology ª 2012 RCOG
3 Complications of Essure Ò sterilisation Results The mean age of the sample was 36 years, ranging from 19 to 49 years, with 1306 women aged years, 2687 aged years, 315 aged years and three women who were <20 years old. Of the 4306 women undergoing hysteroscopic Essure Ò sterilisation, 4242 (98.5%) were successfully completed, of which 4075 were successfully sited at one attempt (96%), without the need for a second-stage procedure at a later date. A total of 4108 (96.8%) women complied with the 3-month radiological follow-up. The majority of women had follow-up beyond 1 year, with only 534 cases having had the procedure within the previous year (Figure 1). The rate of successful bilateral obstruction (including unilateral occlusion in women with only one tube) was 99.7% (4095/4108). One or both tubes remained patent in 13 women (0.3%), representing a 3.1:1000 failure rate (Figure 2). A total of seven women (0.16%), three before and four after the 3-month follow-up, became pregnant. The pregnancy rate after assessment for satisfactory placement was 0.09%. In one subject who became pregnant 32 months after the procedure, the 3-month control pelvic X-ray and vaginal ultrasound scan suggested that the devices were well placed, and the HSG performed after delivery showed an apparent bilateral occlusion. However, laparoscopy demonstrated a unilateral tubal perforation. The most frequent perioperative complication was vasovagal syncope, occurring in 85 women (1.9%). Of 19 device expulsions (0.4%), 14 occurred during the early postoperative period; in 13 women another device was placed, and in two other women the expulsion was incomplete, and in these cases the coils trailing into the cavity were cut. Subsequent HSG demonstrated correct bilateral tubal obstruction. In three cases the devices were erroneously placed in Figure 1. Length of follow-up of women undergoing Essure â sterilisation. 42 one tube (Salpinguectomy or unicornuate uterus) 4095 (99.6%) success obstructions 4108 (96.8%) 3 months radiology* the myometrium (0.06%). In two other cases, asymptomatic migrations into the abdominal cavity (0.04%) were detected, as were two cases of pelvic inflammatory disease (0.04%). Both women with abdominal migration of one device underwent another placement, retaining the migrated devices in the abdominal cavity. Longer term complications included one woman who suffered persistent abdominal pain (0.02%) and one women with tubal perforation (0.02%). Two allergies to nickel were noted. The first case was a woman with a history of atopy, who presented shortly after the procedure with papular urticaria and erythema, and in whom the symptoms disappeared after the subsequent removal of both devices. The other case was a woman referred with a history of persistent genital pruritus 1 year after the placement who decided to remove the devices. In 3568 women (82.8%), the perioperative pain was considered non-existent or mild, which was managed with oral nonsteroidal anti-inflammatory drugs (NSAIDS). Moderate pain was reported by 513 (11.9%) women, and severe pain was reported by 155 women (3.5%). In 70 cases (1.5%) pain was not recorded at all. One subject experienced persistent abdominal pain that did not disappear with NSAIDS. As the pain remained after the removal of the devices, a prophylactic appendicectomy and cholecystectomy was performed, but the pain continued to persist. This woman is currently receiving treatment with antidepressant drugs. Discussion 4242 (98.5%) Successful insertion 13 (0.3%) unsuccessful obstructions 4306 Patients 4200 both tubes 29 no insertion one tube 134 (3.2%) lost to follow up 64 (1.5%) no insertion 35 no insertion both tubes Figure 2. Flow chart of the trial process (success/failed insertion and obstructions with Essure â ). *Abdominal X-ray, transvaginal ultrasound and/or hysterosalpinogram. This study has demonstrated Essure Ò hysteroscopic sterilisation to be a successful and safe procedure. No adverse ª 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology ª 2012 RCOG 797
4 Povedano et al. events identified were associated with serious long-term medical problems. Indeed 75% of complications were minor, self-limiting episodes of vasovagal syncope, a phenomenon associated with any form of uterine instrumentation, and not specific to the Essure Ò procedure. Interestingly, a higher incidence of vasovagal syncope was observed in interventions performed by gynaecologists with a shorter learning curve. 1 Techniques aimed at reducing the incidence of vasovagal syncope include performing the procedure with smaller diameter instruments (avoiding the use of the outflow channel) and reducing the intrauterine pressure provided by the perfusion pump to 90 mmhg on the appearance of vasovagal symptoms, although there is no evidence to support these manoeuvres at present. No serious sequelae arose from the abnormal placement of the device. Among the 19 device expulsions recorded, another device was placed in 13 of the women, and 3 months later the HSG performed to assess the location of the device demonstrated secondary bilateral tube obstructions. In two other cases, the expulsion was partially towards the endometrial cavity, and the coils seen in the cavity were cut, showing a correct bilateral obstruction on HSG. In the two cases of cavity migration a new device was placed without the removal of the migrated devices. Both patients remain asymptomatic, without pain, infection symptoms or gastrointestinal symptoms. Nickel allergies affect 17% of women, 16 representing 721 cases of expected nickel allergies in 4242 placements. Nonetheless, in this series only two women presented with an allergy to nickel. This low incidence could be explained by the very low proportion of nickel in the devices, and thus allergy symptoms only develop in a very small number of patients who are extremely sensitive to this element. Pelvic inflammatory disease is uncommon after hysteroscopy. Only two cases of pelvic inflammatory disease were observed in this series, both of which resolved after treatment with endovenous antibiotics. Our results are in agreement with those described by others. In a prospective study including 1952 surgical hysteroscopies, only 18 endometritis and 12 urinary tract infections, but no cases of pelvic inflammatory disease, were observed. 17 Another recent study reported two cases (79%) of pelvic inflammatory disease after 253 diagnostic hysteroscopies. 18 Therefore, prophylactic antibiotic treatment prior to the Essure Ò procedure is not recommended. Our series supports the contention that Essure Ò hysteroscopic sterilisation is acceptable, with <5% of women considering the pain experienced during the procedure as severe, and is effective at preventing pregnancy, with only seven pregnancies reported in over 4000 procedures. Of these seven procedures that resulted in pregnancy, three women did not comply with the follow-up protocol and became pregnant prior to confirmatory radiological testing. Of the four true method failures (i.e. women who became pregnant after apparently successful procedures), one case is of note as it occurred over 3 years after the procedure. An HSG at 3 months had shown an apparent bilateral occlusion. The woman decided to continue with the pregnancy, and after delivery laparoscopy showed a right tubal perforation. 19 This highlights the need for long-term data regarding the effectiveness of Essure Ò sterilisation in preventing pregnancy so as to better aid the counselling and informed consenting of our patients. Our series is the largest to date evaluating the feasibility, safety and effectiveness of Essure Ò hysteroscopic sterilisation. We identified all women undergoing the procedure. However, the incidence of adverse events post-operatively may be an underestimate as we relied upon self-reporting. However, we did emphasise the importance of reporting any complications to our unit via telephone, and complications were enquired about at each consultation. Moreover, healthcare professionals in primary care and peripheral centres were encouraged to report any adverse events presumed to have arisen from the procedure. We relied upon pelvic X-ray examination to confirm the adequacy of sterilisation, although the accuracy of pelvic X-ray has been questioned compared with TVU or HSG. 20 Whereas it is likely that some complications may have remained undetected, we believe that it is unlikely that any major adverse events, such as pelvic inflammatory disease or pregnancy, occurred without our knowledge. In conclusion, our results, the largest series by far to date, support existing data demonstrating that outpatient clinic tubal hysteroscopic sterilisation with Essure Ò is feasible, successful and safe. Disclosure of interests The authors have received expenses from Conceptus (the manufacturer of Essure Ò ) to attend scientific meetings and congresses. Contribution to authorship BP was involved in the conception and design of the study, performed procedures, managed the inclusion and followup of participants, collected and analysed data, and approved the final version of the article. JEA was involved in the conception and design of the study, performed procedures, managed the inclusion and follow-up of participants, collected and analyses data, and approved the final version of the article. EV performed procedures, managed the inclusion and follow-up of participants, collected data and approved the final version of the article. JAM performed procedures, managed the inclusion and follow-up of participants, collected data and approved the final version of the article. JL performed procedures, collected data, reviewed the article and approved the final version. CC-B was 798 ª 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology ª 2012 RCOG
5 Complications of Essure Ò sterilisation involved in the conception and design of the study, performed statistical analyses, performed the final analysis of the data, drafted and revised the article for important intellectual content, and approved the final version. Details of ethics approval The study was performed in a regular practice, and all the women demonstrated comprehension after the explanation of the procedure and signed a written consent that emphasised the irreversibility of the procedure, and included the possibility of failure to achieve sterilisation at first attempt. IRB Reina Sofia University Hospital. January Funding None to declare. j References 1 Miño M, Arjona J, Cordón J, Pelegrín B, Povedano B, Chacón E. Success rate and patient satisfaction with the EssureTM sterilisation in an outpatient setting: a prospective study of 857 women. BJOG 2007;114: Sinha D, Kalathy V, Gupta J, Clark T. The feasibility, success and patient satisfaction associated with outpatient hysteroscopic sterilisation. BJOG 2007;114: Arjona JE, Miño M, Cordon J, Povedano B, Pelegrin B, Castelo- Branco C. Satisfaction and tolerance with office hysteroscopic tubal sterilisation. Fertil Steril 2008;90: Duffy S, Marsh F, Rogerson L, Hudson H, Cooper K, Jack S, et al. Female sterilisation: a cohort controlled comparative study of ESSURE versus laparoscopic sterilisation. BJOG 2005;112: Kerin JF, Cooper JM, Price T, Herendael BJ, Cayuela-Font E, Cher D, et al. Hysteroscopic sterilisation using a microinsert device: results of a multicentre phase II study. Hum Reprod 2003;18: Panel P, Grosdemouge I. Predictive factors of Essure_ implant placement failure: prospective, multicenter study of 495 patients. Fertil Steril 2010;93: Smith RD. Contemporary hysteroscopic methods for female sterilisation. Int J Gynecol Obstet 2010;108: Escobedo LG, Peterson HB, Grubb GS, Franks AL. Case fatality notes for tubal sterilisation in US hospitals 1979 to Am J Obstet Gynecol 1989;160: Garry R. Towards evidence-based laparoscopic entry techniques: clinical problems and dilemmas. Gynaecol Endosc 1999;8: Phillips K. Hysteroscopic sterilisation: is laparoscopic sterilisation a thing of the past? BJOG 2007;114: Litta P, Cosmi E, Sacco G, Saccardi C, Ciavattini A, Ambrosini G. Hysteroscopic permanent tubal sterilisation using a nitinol-dacron intratubal device without anaesthesia in the outpatient setting: procedure feasibility and effectiveness. Hum Reprod 2005;20: Langenveld J, Veersema S, Bongers MY, Koks CA. Tubal perforation by Essure: three different clinical presentations. Fertil Steril 2008;90:2011.e5 e Gerritse MB, Veersema S, Timmermans A, Brölmann AM. Incorrect position of Essure microinserts 3 months after successful bilateral placement. Fertil Steril 2009; 91:930.e1 e5. 14 Hur HC, Mansuria SM, Chen BA, Lee TT. Laparoscopic management of hysteroscopic Essure sterilisation complications: report of 3 cases. J Minim Invasive Gynecol 2008;15: Veersema S, Vleugels M, Moolenaar LM, Janssen C, Brölmann H. Unintended pregnancies after Essure sterilisation in the Netherlands. Fertil Steril 2010;93: Thyssen JP, Jacob P. Metal allergy-a review on exposures, penetration, genetics, prevalence, and clinical implications. Chem Res Toxicol 2010;23: Agostini A. Postoperative infection and surgical hysteroscopy. Fertil Steril 2002;77: Bracco BL. Infectious complications of diagnostic hysteroscopy. Minerva Ginecol 2010;48: Arjona JE, Serrano JJ, Povedano B, Carrasco S, Castelo-Branco C. Unintended pregnancy after long-term Essure microinserts placement. Fertil Steril 2010;94: Veersema S, Mol BWJ, Hans AM, Brölmann HAM. Reproducibility of the interpretation of pelvic x-ray 3 months after hysteroscopic sterilisation with Essure. Fertil Steril 2010;94: ª 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology ª 2012 RCOG 799
Satisfaction and tolerance with office hysteroscopic tubal sterilization
TECHNIQUES AND INSTRUMENTATION Satisfaction and tolerance with office hysteroscopic tubal sterilization Jose E. Arjona, M.D., Ph.D., a Monica Mi~no, M.D., Ph.D., a Javier Cordon, M.D., Ph.D., a Balbino
More informationFemale sterilisation: a cohort controlled comparative study of ESSURE versus laparoscopic sterilisation
BJOG: an International Journal of Obstetrics and Gynaecology November 2005, Vol. 112, pp. 1522 1528 DOI: 10.1111/j.1471-0528.2005.00726.x Female sterilisation: a cohort controlled comparative study of
More informationESSURE A RESOURCE FOR CODING
ESSURE REIMBURSEMENT GUIDE A RESOURCE FOR CODING INDICATION Essure is indicated for women who desire permanent birth control (female sterilization) by bilateral occlusion of fallopian tubes. IMPORTANT
More informationNational Institute for Health and Clinical Excellence
National Institute for Health and Clinical Excellence 218_2 Hysteroscopic sterilisation by tubal cannulation and placement of intrafallopian implants Consultation Comments table IPAC date: Thursday 16
More informationUnintended pregnancies after Essure sterilization in the Netherlands
Unintended pregnancies after Essure sterilization in the Netherlands S. Veersema M.P.H. Vleugels L.M. Moolenaar C.A.H. Janssen H.A.M. Brölmann Fertil Steril. 2010;93:35-8. 13 Hysteroscopic Sterilization
More informationProbability of pregnancy after sterilization: a comparison of hysteroscopic versus laparoscopic sterilization,
Contraception xx (2014) xxx xxx Original research article Probability of pregnancy after sterilization: a comparison of hysteroscopic versus laparoscopic sterilization, Aileen M. Gariepy a,, Mitchell D.
More informationAileen M. CON-08309; No of Pages 8. Contraception xx (2014) xxx xxx
CON-08309; No of Pages 8 1 Original research article 2 Probability of pregnancy after sterilization: a comparison of hysteroscopic 3 versus laparoscopic sterilization, 4Q1 Aileen M. 5 6 7 Contraception
More informationMEDICAL POLICY SUBJECT: FEMALE STERILIZATION. POLICY NUMBER: CATEGORY: Contract Clarification
MEDICAL POLICY SUBJECT: FEMALE STERILIZATION PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationClinical Experience With Contrast Infusion Sonography as an Essure Confirmation Test
ORIGINAL RESEARCH Clinical Experience With Contrast Infusion Sonography as an Essure Confirmation Test Viviane F. Connor, MD Received November 3, 2010, from the Department of Gynecology, Section of Minimally
More informationHysteroscopic Tubal Sterilization: An Evidence-Based Analysis
Hysteroscopic Tubal Sterilization: An Evidence-Based Analysis K McMartin October 2013 Ontario Health Technology Assessment Series; Vol.13: No. 21, pp. 1 35, October 2013 Suggested Citation This report
More informationLabeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization Draft Guidance for Industry and Food and Drug
More informationMyometrial Insertion of Essure Mirco-Insert
Case Report http://www.alliedacademies.org/research-and-reports-in-gynecology-and-obstetrics Myometrial Insertion of Essure Mirco-Insert Jeffrey J Woo 1*, Barbara E Simpson 1, Dale W Stovall 2 1 Department
More informationCase Report Essure Surgical Removal and Subsequent Resolution of Chronic Pelvic Pain: A Case Report and Review of the Literature
Case Reports in Obstetrics and Gynecology Volume 2016, Article ID 6961202, 5 pages http://dx.doi.org/10.1155/2016/6961202 Case Report Essure Surgical Removal and Subsequent Resolution of Chronic Pelvic
More informationV. Mijatovic S. Veersema M.H. Emanuel R. Schats P.G. Hompes. Fertil Steril. 2010;93:
Essure hysteroscopic tubal occlusion device for the treatment of hydrosalpinx prior to in vitro fertilization-embryo transfer in patients with a contraindication for laparoscopy. V. Mijatovic S. Veersema
More informationPermanent Sterilization: When you are really sure!
Permanent Sterilization: When you are really sure! Tony Ogburn MD Department of Ob/Gyn 2006-8 National Survey of Family Growth 6.1% of women had a sterilized male partner The History of Female Sterilization
More informationCLINICAL GUIDELINES ID TAG Female Sterilisation (tubal occlusion) at Caesarean Section- Guideline for counselling and consent
Title: Author: Designation: Speciality / Division: Directorate: CLINICAL GUIDELINES ID TAG Female Sterilisation (tubal occlusion) at Caesarean Section- Guideline for counselling and consent Dr Meeta Kamath
More informationEssure Permanent Birth Control Device: Radiological followup results at our center
Essure Permanent Birth Control Device: Radiological followup results at our center Poster No.: C-0212 Congress: ECR 2013 Type: Scientific Exhibit Authors: R. Díaz Aguilera, A. M. Higuera Higuera, V. Palomo
More informationTranscervical Sterilization
Q UESTIONS & ANSWERS A BOUT Transcervical Sterilization A New Choice in Permanent Birth Control Choosing a Birth Control Method Women and their partners now have more birth control choices than ever. How
More informationEssure By Mayo Clinic staff
Page 1 of 5 Reprints A single copy of this article may be reprinted for personal, noncommercial use only. Essure By Mayo Clinic staff Original Article: http://www.mayoclinic.com/health/essure/my00999 Definition
More informationSIMPLE PERMANENT CONTRACEPTION A HIGHLY EFFECTIVE AND COMPLICATION FREE BIRTH CONTROL DEVICE
CONSIDER WHAT IS BEST FOR YOU... SIMPLE PERMANENT CONTRACEPTION A HIGHLY EFFECTIVE AND COMPLICATION FREE BIRTH CONTROL DEVICE Effective. Safe. Proven. FILSHIE - THE CLIP, A HIGHLY EFFECTIVE CHOICE FOR
More informationFemale sterilization by the natural pathways
info-canada@conceptus.com www.essure.com Female sterilization by the natural pathways magazine 1.Hatcher R et al. Contraceptive Technology, 17 th Edition. New York : Ardent Media, 1998. 2. Bhiwandiwala
More informationClinical Policy: Essure Removal Reference Number: CP.MP.131
Clinical Policy: Reference Number: CP.MP.131 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationUpdate on the Essure System for Permanent Birth Control
Update on the Essure System for Permanent Birth Control Heidi Collins Fantasia IIn 2002, the U.S. Food and Drug Administration (FDA) approved Essure (Bayer, Whippany, NJ), a minimally invasive procedure
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of microwave endometrial ablation Introduction This overview has been prepared to assist
More informationConsider what is best for you...
Consider what is best for you... PERMANENT CONTRACEPTION A HIGHLY EFFECTIVE AND COMPLICATION FREE BIRTH CONTROL DEVICE Effective. Safe. Proven. FILSHIE - THE CLIP, EASY TO CORRECTLY APPLY Quick laparoscopic
More informationFamily Planning Eligibility Program
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Family Planning Eligibility Program L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 5 3 P U B L I S H E D : N O V E M B E R 2
More informationChapter 2. Implementation of hysteroscopic surgery in The Netherlands. Heleen van Dongen Wendela Kolkman Frank Willem Jansen
Chapter 2 Implementation of hysteroscopic surgery in The Netherlands Heleen van Dongen Wendela Kolkman Frank Willem Jansen Adapted from Eur J Obstet Gynecol Reprod Biol 07;132:232-236 Introduction Diagnostic
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of sterilisation by insertion of intrafallopian implants Sterilisation is sometimes
More informationESSURE CLINICAL RESOURCE
ESSURE CLINICAL RESOURCE Physician Training Manual IMPORTANT SAFETY INFORMATION WARNING: Some patients implanted with the Essure System for Permanent Birth Control have experienced and/or reported adverse
More informationCommissioning Policy Individual Funding Request
Commissioning Policy Individual Funding Request Female Sterilisation Prior Approval Policy Date Adopted: 6 th February 2017 Version: 1617.1 Individual Funding Request Team - A partnership between Bristol,
More informationLaparoscopy-Hysteroscopy
Laparoscopy-Hysteroscopy Patient Information Laparoscopy The laparoscope, a surgical instrument similar to a telescope, is inserted through a small incision (cut) in the belly button during laparoscopy.
More informationSterilisation for women at the RD&E: what you need to know Reference Number: CW
Sterilisation for women at the RD&E: what you need to know Royal Devon and Exeter NHS Foundation Trust Patient Information Sterilisation for Women at The Royal Devon and Exeter Hospital What you need to
More informationMicroinsert Nonincisional Hysteroscopic Sterilization
Microinsert Nonincisional Hysteroscopic Sterilization Jay M. Cooper, MD, Charles S. Carignan, MD, Daniel Cher, MD, and John F. Kerin, MD, for the Selective Tubal Occlusion Procedure 2000 Investigators
More informationExcessive menstrual blood loss
Ian Chilcott Excessive menstrual blood loss >80mls - That interferes with physical, emotional, social and material quality of life 1 in 20 women aged 30 to 49 years consult their GP each year with menorrhagia
More informationOutpatient hysteroscopy direct diagnostic access & new therapeutic procedures
Outpatient hysteroscopy direct diagnostic access & new therapeutic procedures Mrs Katy Clifford Consultant Gynaecologist St Mary s Hospital Imperial College Healthcare NHS Trust Diagnostic outpatient hysteroscopy
More informationCODING GUIDELINES FOR CONTRACEPTIVES. Effective June 1, 2017 Version 1.40
CODING GUIDELINES FOR CONTRACEPTIVES Effective June 1, 2017 Version 1.40 TABLE OF CONTENTS ICD-10 CM Diagnosis Codes: Encounter for Contraception page 2 Coding for IUD Insertion and Removal Procedures
More informationImaging evaluation of gynaecological devices
Imaging evaluation of gynaecological devices Poster No.: C-0850 Congress: ECR 2013 Type: Educational Exhibit Authors: R. M. Lorente Ramos, J. Azpeitia Arman, P. Aparicio Rodríguez- 1 1 1 1 1 Miñón, F.
More informationChapter 1. Chapter 2. Chapter 3
Summary To perform IUI some conditions are required. This includes 1) a certain amount of progressively motile spermatozoa, 2) the presence of ovulation, 3) the presence of functional fallopian tubes,
More informationInvestigating HMB- an evidence based approach
BSGE Meeting: Contemporary management of heavy menstrual bleeding (HMB) in primary and secondary care: (7 th December 2018, RCOG) Investigating HMB- an evidence based approach T. Justin Clark MB ChB, MD(Hons),
More informationHysteroscopy - current trends and challenges
J Obstet Gynecol India Vol. 58, No. 1 : January/February 2008 pg 57-62 Original Article Hysteroscopy - current trends and challenges Gour A, Zawiejska A, Mettler L Department of Obstetrics and Gynaecology,
More informationFigure 1b: Essure Insert (NOT TO SCALE) (NOT TO SCALE)
Figure 1b: Essure Insert Expanded configuration, detached from the delivery system (NOT TO SCALE) WARNING: Some patients implanted with the Essure System for Permanent Birth Control have experienced and/or
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationDr John Short. Obstetrician and Gynaecologist Christchurch Women s Hospital Oxford Women's Health Christchurch
Dr John Short Obstetrician and Gynaecologist Christchurch Women s Hospital Oxford Women's Health Christchurch 16:30-17:30 WS #125: Everything GPs Should Know About Gynaecologists 17:35-18:30 WS #135: Everything
More informationRole of diagnostic hysteroscopy in evaluation of abnormal uterine bleeding and its histopathological correlation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chaudhari KR et al. Int J Reprod Contracept Obstet Gynecol. 2014 Sep;3(3):666-670 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationTHE WOMAN-FRIENDLY STERILIZATION METHOD
THE WOMAN-FRIENDLY STERILIZATION METHOD Urogyn BV Transistorweg 5a 6534 AT Nijmegen The Netherlands t +31(0) 24 711 41 30 info@urogynbv.com www.urogynbv.com THE MOST WOMAN-FRIENDLY STERILIZATION METHOD
More informationHysteroscopic Essure Inserts for Permanent Contraception Extended Follow-up Results of a Phase III, Multicenter, International Study
Accepted Manuscript Hysteroscopic Essure Inserts for Permanent Contraception Extended Follow-up Results of a Phase III, Multicenter, International Study Scott G. Chudnoff, MD, MS, John E. Nichols, Jr.,
More informationPermanent contraception for women
For reprint orders, please contact: reprints@futuremedicine.com Permanent methods of contraception are used by an estimated 220 million couples worldwide, and are often selected due to convenience, ease
More informationfemale steri e sterilisation female sterilisation male and female sterilisation male sterilisation emale sterilisation female male sterilisati
your guide to male and female sterilisation Helping you choose the method of contraception that is best for you female sterilisati le sterilisation male sterilisation e sterilisation female female ster
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationFibroid mapping. Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital
Fibroid mapping Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital Fibroids Common condition >70% of women by onset of menopause.
More informationFigure 1b: Essure Insert (NOT TO SCALE)
Figure 1b: Essure Insert Expanded configuration, detached from the delivery system (NOT TO SCALE) WARNING: Some patients implanted with the Essure System for Permanent Birth Control have experienced and/or
More informationFemale Sterilization. Kavita Nanda, MD, MHS FHI 360 Expanding Contraceptive Choice December 6, 2018
Female Sterilization Kavita Nanda, MD, MHS FHI 360 Expanding Contraceptive Choice December 6, 2018 What is female sterilization? Family planning method that provides permanent contraception to women and
More informationOne-step transvaginal three-dimensional hysterosalpingofoam sonography (3D-HyFoSy) confirmation test for Essure follow-up: a multicenter study
Ultrasound Obstet Gynecol 2018; 51: 134 141 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.17398 One-step transvaginal three-dimensional hysterosalpingofoam sonography
More informationFDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections
More informationLaparoscopy and Hysteroscopy
AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Laparoscopy and Hysteroscopy A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of
More informationHysteroscopic Tubal Occlusion for Contraception
Hysteroscopic Tubal Occlusion for Contraception (Essure and Adiana Systems) Policy Number: 2014M0056A Effective Date: June 1, 2014 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION 2
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of balloon thermal endometrial ablation (Cavaterm) Introduction This overview has been prepared
More informationClinics in diagnostic imaging (110)
M e d i c a l E d u c a t i o n Singapore Med Med J 2006; J 2006; 47(7) 47(7) : 642 : 1 Clinics in diagnostic imaging (110) Lim S Y, Lam S L Fig. 1 Radiograph of the pelvis. Fig. 2 Sagittal and coronal
More informationYour visit to the Outpatient Hysteroscopy Clinic
Your visit to the Outpatient Hysteroscopy Clinic Department of Gynaecology Patient Information What What is the is an Outpatient outpatient Cystoscopy hysteroscopy? Clinic? An outpatient hysteroscopy means
More informationConsent Advice No. XX (Joint with BSGE) Peer Review Draft Spring Morcellation for Laparoscopic Myomectomy or Hysterectomy
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 Consent Advice No. XX (Joint with BSGE) Peer Review Draft
More informationCan diagnostic laparoscopy be avoided in routine investigation for infertility?
BJOG 000,10(), pp. 118 Can diagnostic laparoscopy be avoided in routine investigation for infertility? N. P. Johnson Senior Registrar, K. Taylor Medical Student, A. A. Nadgir Specialist Registrar, D. J.
More informationHysteroscopic sterilization using a micro-insert device: results of a multicentre Phase II study*
Human Reproduction Vol.18, No.6 pp. 1223±1230, 2003 DOI: 10.1093/humrep/deg256 Hysteroscopic sterilization using a micro-insert device: results of a multicentre Phase II study* John F.Kerin 1,8, Jay M.Cooper
More informationInstruction for the patient
Instruction for the patient Your situation You are a 38-year-old, woman who is pregnant with her third child You and your partner agree that with this child your family is complete In the past, you used
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationreproducibility of the interpretation of hysterosalpingography pathology
Human Reproduction vol.11 no.6 pp. 124-128, 1996 Reproducibility of the interpretation of hysterosalpingography in the diagnosis of tubal pathology Ben WJ.Mol 1 ' 2 ' 3, Patricia Swart 2, Patrick M-M-Bossuyt
More informationHeavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist
Heavy Menstrual Bleeding Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist Why is HMB so important? 1:20 women aged 30-49 consult their GP with HMB Once referred to gynaecologist, surgical
More informationBirth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy
Birth Control- an Overview Keith Merritt, MD Basics Remember, all methods of birth control are safer and have fewer side effects than pregnancy Even with perfect use, each method of birth control has a
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationTissue Morcellation: Managing Risks to Drive Best Patient Outcomes
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCitation for published version (APA): Timmermans, A. (2009). Postmenopausal bleeding : studies on the diagnostic work-up
UvA-DARE (Digital Academic Repository) Postmenopausal bleeding : studies on the diagnostic work-up Timmermans, A. Link to publication Citation for published version (APA): Timmermans, A. (2009). Postmenopausal
More informationGynaecology. Pelvic inflammatory disesase
Gynaecology د.شيماءعبداألميرالجميلي Pelvic inflammatory disesase Pelvic inflammatory disease (PID) is usually the result of infection ascending from the endocervix causing endometritis, salpingitis, parametritis,
More informationThe impact of an assisted conception unit on the workload of a general gynaecology unit
BJOG: an International Journal of Obstetrics and Gynaecology February 2002, Vol. 109, pp. 207 211 The impact of an assisted conception unit on the workload of a general gynaecology unit Joanne McManus*,
More informationSalpingo(s)tomy versus salpingectomy for tubal pregnancy; impact on future fertility
Patient registration label Salpingo(s)tomy versus salpingectomy for tubal pregnancy; impact on future fertility CASE RECORD FORM Patient Identification Number European Surgery in Ectopic Pregnancy study
More informationPelvic inflammatory disease - spectrum of tomodensitometric findings
Pelvic inflammatory disease - spectrum of tomodensitometric findings Poster No.: C-2451 Congress: ECR 2015 Type: Educational Exhibit Authors: E. Matos, A. T. Almeida, D. Castelo; Vila Nova de Gaia/PT Keywords:
More informationLaparoscopy and Related Procedures
Laparoscopy and Related Procedures Introduction The operation of laparoscopy is also commonly known as a keyhole operation. Laparoscopy can be used as a diagnostic procedure (i.e. an operation to find
More informationMENSTRUAL PATTERNS AND WOMEN'S ATTITUDES FOLLOWING STERILIZATION BY FA LOPE RINGS*
FERTILITY AND STERILITY Copyright 1979 The American Fertility Society Vol. 31, No.6, June 1979 Printed in U.s.A. MENSTRUAL PATTERNS AND WOMEN'S ATTITUDES FOLLOWING STERILIZATION BY FA LOPE RINGS* LIDIA
More informationMyometrial scoring: a new technique for the management of severe Asherman s syndrome
FERTILITY AND STERILITY VOL. 69, NO. 5, MAY 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Myometrial scoring: a
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationBirth Control Options Chart
Hormonal Methods Birth control pills also known as mini-pills 91-99% A daily pill containing hormones that stops you from ovulating. There are combination estrogen or progestin-only (mini-pill) options.
More informationExamining Long-Acting Reversible Contraceptive Methods
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/examining-long-acting-reversible-contraceptivemethods/7078/
More informationPrescriber and Pharmacy Guide for the Opsumit REMS Program
Prescriber and Pharmacy Guide for the Opsumit REMS Program (Risk Evaluation and Mitigation Strategy) including BOXED WARNING for teratogenicity. Risk of teratogenicity Introduction to Opsumit (macitentan)
More informationJohn R. Randolph, Jr., M.D.t Yu Kang Ying, M.D.:j: Donald B. Maier, M.D. Cecilia L. Schmidt, M.D. Daniel H. Riddick, M.D., Ph.D.1I
FERTILITY AND STERILITY Copyright 1986 The American Fertility Society Vol. 46. No.5. November 1986 Prinred in U.s A. Comparison of real-time ultrasonography, hysterosalpingography, and laparoscopy/hysteroscopy
More informationSurgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk
Surgery to Reduce the Risk of Ovarian Cancer Information for Women at Increased Risk Centre for Genetics Education NSW Health 2017 The Centre for Genetics Education NSW Health Level 5 2C Herbert St St
More informationSTOP/START. On the Web. 12 intraoperative videos from Dr. Garcia, at
Diagnostic hysteroscopy spies polyp previously missed on transvaginal ultrasound and dilation and curettage. STOP performing dilation and curettage for the evaluation of abnormal uterine bleeding START
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of laparoscopic laser myomectomy Introduction This overview has been prepared to assist
More informationCase Report. Introduction. E. Scott Sills 1-3, Gianpiero D. Palermo 4
Case Report Obstet Gynecol Sci 2016;59(4):337-341 http://dx.doi.org/10.5468/ogs.2016.59.4.337 pissn 2287-8572 eissn 2287-8580 Combined hysteroscopy-laparoscopy approach for excision of pelvic nitinol fragment
More informationTUBAL PLASTIC SURGERY is an accepted form of therapy in the treatment
Tubal Plastic Surgery ADNAN MROUEH, M.D., ROBERT H. GLASS, M.D., and C. LEE BUXTON, M.D. TUBAL PLASTIC SURGERY is an accepted form of therapy in the treatment of infertility. However, reports have differed
More informationEvaluation of the Infertile Couple
Overview and Definition Infertility is defined as the inability of a couple to fall pregnant after one year of unprotected intercourse. Infertility is a very common condition as in any given year about
More informationAn Overview of Uterine Factors That Influence Implantation
An Overview of Uterine Factors That Influence Implantation Bulent Urman, M.D. Dept. of Obstetrics and Gynecology Koc University School of Medicine Assisted Reproduction Unit, American Hospital, ISTANBUL
More informationKUALA LUMPUR SUMMARY MATERIALS AND METHODS INTRODUCTION
Med. J. Malaysia Vol. 37 No. 3 September 1982. WITH HULKA CLIPS AT THE UNIVERSITY KUALA LUMPUR ASARI ABDUL RAHMAN V. SIVANESARATNAM A. ADLAN NURUDDIN SUMMARY An analysis of 86 patients sterilized laparoscopically
More informationSurgery and Infertility
Surgery and Infertility Dr Phill McChesney BHB MBChB FRANZCOG MRMed CREI Laparoscopy Prior to Considering IVF Diagnostic Tubal Surgery Treatment of peritubal adhesions Reconstructive surgery Sterilization
More informationENDOSCOPIC TREATMENT OF UTERINE MALFORMATIONS
ENDOSCOPIC TREATMENT OF UTERINE MALFORMATIONS PROF. ANTONIO PERINO CATTEDRA DI GINECOLOGIA OSTETRICIA E FISIOPATOLOGIA DELLA RIPRODUZIONE UMANA UNIVERSITA DEGLI STUDI DI PALERMO Mullerian duct malformations
More informationEvidence Based Guideline Intrauterine Ablation or Resection of the Endometrium
Evidence Based Guideline Intrauterine Ablation or Resection of the Endometrium File Name: intrauterine_ablation_or_resection_of_the_endometrium Guideline Number: EBG.OBGYN3030 Origination: 4/1993 Last
More informationIndian Journal of Basic and Applied Medical Research; September 2015: Vol.-4, Issue- 4, P
Original article: To study post intrauterine insemination conception rate among infertile women with polyp and women with normal uterine endometrium cavity 1Dr. Archana Meena, 2 Dr. Renu Meena, 3 Dr. Kusum
More informationIs Outpatient Hysteroscopy the New Gold Standard?
Is Outpatient Hysteroscopy the New Gold Standard? McIlwaine K, Readman E, Ma T, Manwaring J, Ellett L, Hicks L, Porter J, Cameron M, Maher P. Mercy Hospital for Women, Melbourne, Australia Background Abnormal
More informationInformation for Informed Consent for Insertion of a Mirena IUD
Information for Informed Consent for Insertion of a Mirena IUD What is an IUD (intrauterine Device)? An intrauterine device (IUD) is a plastic device that is placed into your uterus to prevent pregnancy.
More informationComparison of Hysterosalpingography and Combined Laparohysteroscopy for the Evaluation of Primary Infertility Nigam A, 1 Saxena P, 2 Mishra A 2
Comparison of Hysterosalpingography and Combined Laparohysteroscopy for the Evaluation of Primary Infertility Nigam A, 1 Saxena P, 2 Mishra A 2 ABSTRACT Background 1 Department of Obstetrics and Gynaecology
More informationContraception. IUC s, Sterilization
Contraception IUC s, Sterilization Intrauterine Contraceptives (IUC s) IUC s are made of flexible plas4c, available only through prescrip4on Three types ParaGard (copper) Mirena (hormone) Skyla (hormone)
More informationPALM-COEIN: Your AUB Counseling Guide
PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More information